MAPT and early-onset autosomal dominant Alzheimer disease: AsymAD is a preclinical phase of Alzheimer’s disease (AD) observed in ~20–30% of cognitively intact elderly individuals who nonetheless harbor substantial amyloid and Tau pathology at autopsy5–7.